The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Zomig Rapimelt 2.5 mg orodispersible Tablets

2.5 milligram(s) Orodispersible tablet

Grunenthal Pharma LtdPA2242/004/002

Main Information

Trade NameZomig Rapimelt 2.5 mg orodispersible Tablets
Active SubstancesZolmitriptan
Strength2.5 milligram(s)
Dosage FormOrodispersible tablet
Licence HolderGrunenthal Pharma Ltd
Licence NumberPA2242/004/002

Group Information

ATC CodeN02CC Selective serotonin (5HT1) agonists
N02CC03 zolmitriptan


Licence Issued01/10/1999
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back